CD8A and neoplasm: Given that SLC25A22 is predominantly expressed in epithelial cells, it may play a significant role in modulating the function of CD8+ T cells and immunotherapeutic response.[25] We hypothesize that targeting SLC25A22 could modulate the cytotoxicity of CD8+ T cells by influencing the communication between tumor cells and T cells.